Imunon develops DNA‑based immunotherapies and nucleic acid vaccines that use non‑viral delivery platforms to program cells to produce therapeutic proteins such as IL‑12 or multivalent antigens in situ. The TheraPlas™ and PlaCCine systems enable localized, sustained immune activation for oncology and infectious disease applications while simplifying manufacturing and distribution.
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer and infectious disease treatments often rely on protein-based drugs or viral vectors, which can be limited by manufacturing complexity, safety concerns, and insufficient immune activation, especially for hard‑to‑treat cancers like advanced ovarian cancer and emerging viral threats.
Solution
Imunon creates DNA‑based immunotherapies and nucleic acid vaccines that program the body’s own cells to produce therapeutic proteins in situ, generating potent and durable immune responses. Its non‑viral delivery platforms—TheraPlas™ for oncology and PlaCCine for infectious disease—enable local production of immune‑modulating agents such as IL‑12 or multivalent antigens without the need for viral carriers. Clinical programs include IMNN‑001, a TheraPlas™‑based IL‑12 therapy showing proof‑of‑concept in advanced ovarian cancer, and IMNN‑101, a PlaCCine‑based SARS‑CoV‑2 vaccine demonstrating robust antibody and T‑cell durability. By leveraging synthetic DNA and proprietary delivery systems, Imunon aims to provide scalable, safe, and effective treatments for diseases with high unmet need.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology or infectious disease therapies, as well as clinical research organizations seeking non‑viral DNA platforms for vaccine and immunotherapy programs.
Features
- Non‑viral synthetic DNA platforms (TheraPlas™, PlaCCine, FixPlas, IndiPlas) that deliver plasmid constructs directly to target tissues.
- Localized in‑body expression of therapeutic proteins, enabling sustained immune activation with reduced systemic toxicity.
- IL‑12 expression via TheraPlas™ for tumor micro‑environment modulation, demonstrated clinical activity in ovarian cancer (Phase 2 OVATION trial).
- Multivalent plasmid vaccine design on PlaCCine platform, eliciting both strong humoral (IgG, neutralizing antibodies) and cellular (T‑cell) responses with >12‑month durability.
- Cold‑chain‑compatible DNA formulations stable at 4 °C for at least 12 months, simplifying distribution.
- Scalable manufacturing using plasmid DNA production, avoiding complex biologics or viral vector processes.